Tag: Nerimas

  • New brain-mapping study suggests psychedelics mute visual reality and amplify memory signals

    New brain-mapping study suggests psychedelics mute visual reality and amplify memory signals

    Psychedelic substances act on the brain by binding to serotonin receptors. Scientists have identified at least 14 different receptors that respond to the neurotransmitter serotonin. Psychedelics are especially drawn to one known as the 2A receptor. This receptor not only affects learning but also dampens activity in parts of the brain responsible for processing visual information.

    “We have observed in earlier studies that visual processes in the brain are suppressed by this receptor,” says Callum White, first author of the study. “This means that visual information about things happening in the outside world becomes less accessible to our consciousness. To fill this gap in the puzzle, our brain inserts fragments from memory — it hallucinates.”

    In other words, when incoming visual signals are reduced, the brain compensates by pulling stored images and experiences from memory. Those internally generated fragments can blend into perception, producing hallucinations.

    Slow Brain Waves Shift Perception Toward Memory

    The researchers also uncovered how this shift unfolds in real time. Psychedelics increase rhythmic patterns of brain activity, known as oscillations, in visual regions. Oscillations are coordinated waves of neural firing that help different parts of the brain communicate with each other.

    After psychedelics were administered, the team observed a rise in low-frequency (5-Hz) waves in visual areas. These slower waves stimulated another region called the retrosplenial cortex, a key hub involved in accessing stored memories. As this communication strengthens, the brain enters a different operating mode. Awareness of current external events becomes weaker, while perception relies more heavily on recalled information. As Professor Dirk Jancke, who led the study, describes it, the experience is “a bit like partial dreaming.”

    Real-Time Brain Imaging Reveals the Mechanism

    To capture these changes, the scientists used an advanced optical imaging technique that tracks neural activity across the entire surface of the brain in real time. The experiments relied on specially engineered mice created by Professor Thomas Knöpfel at Hong Kong Baptist University. These animals were designed to produce fluorescent proteins in specific types of brain cells.

    This approach allowed researchers to pinpoint the source of the signals they recorded. “We therefore know exactly in our experiments that the measured fluorescent signals originate from pyramidal cells of the cortical layers 2/3 and 5, which mediate communication within and between brain regions,” says Jancke. These cells play a central role in transmitting information across the cortex.

    Implications for Depression and Anxiety Treatment

    The findings may also help refine psychedelic-assisted therapy. Researchers believe that, under medical supervision, these substances can temporarily shift brain activity in ways that encourage the recall of positive memories and weaken deeply ingrained negative thought patterns.

    “When used under medical supervision, such substances can temporarily change the state of the brain to selectively recall positive memory content and restructure learned, excessively negative thought patterns, i.e., to be able to unlearn negative context. It will be exciting to see how such therapies are further personalized in the future,” says Jancke.

    By clarifying how psychedelics redirect perception from the outside world to internal memory networks, the study provides a clearer biological explanation for both hallucinations and the growing therapeutic potential of these compounds.

  • Exercise emerges as a leading option for depression and anxiety, with group programs showing the biggest gains

    Exercise emerges as a leading option for depression and anxiety, with group programs showing the biggest gains

    A major evidence review in the British Journal of Sports Medicine reports that structured exercise can meaningfully reduce symptoms of depression and anxiety, often performing as well as established treatments. The authors assessed a large body of randomized trial data to compare different exercise types, intensities and settings.

    The umbrella review combined results from dozens of prior meta-analyses, covering hundreds of individual trials and tens of thousands of participants across a wide age range. Overall, the synthesis found a medium-sized improvement in depression symptoms and a small-to-medium improvement in anxiety.

    Which workouts seemed most effective

    Aerobic exercise such as running, swimming and dance stood out for depression, particularly when sessions were supervised or done in groups. For anxiety, shorter programs lasting up to about 8 weeks and using lower-intensity activity appeared to deliver the most consistent benefits.

    Researchers also found improvements across resistance training and mind-body approaches such as yoga, tai chi and qigong, as well as mixed programs that combine formats. Effects were observed regardless of sex, suggesting exercise can be broadly useful, even if the best “fit” varies by person.

    Who benefited most in the data

    The strongest reductions were reported among young adults ages 18 to 30 and among women after giving birth, groups that also face elevated risks of mood and anxiety symptoms. The authors note that social and practical factors, including support and accountability, may help explain why group formats performed well.

    While the results were generally comparable to medication or talking therapies, the study does not argue that exercise should replace clinical care for everyone. Instead, it points to exercise as a credible first-line or add-on option, especially where access to therapy or medication is limited or where people prefer non-drug approaches.

    Limits and what comes next

    The authors caution that definitions of intensity, frequency and program length differed across studies, making precise prescriptions harder to standardize. Some age groups and exercise formats were also represented by less pooled data than others.

    Even with those caveats, the review strengthens the case for tailoring exercise to individual needs, including supervision, setting and duration. Clinicians increasingly emphasize that the most effective program is one a person can start safely and sustain, while tracking symptoms and overall wellbeing.

  • Study links sugary drinks to teen anxiety, and researchers say the trend may be harder to reverse than parents think

    Study links sugary drinks to teen anxiety, and researchers say the trend may be harder to reverse than parents think

    A new research review has found a consistent association between high consumption of sugary drinks and increased anxiety symptoms among teenagers. The analysis, led by researchers working with Bournemouth University, was published in the Journal of Human Nutrition and Dietetics.

    The team examined results from multiple earlier studies to see whether patterns held across different adolescent groups. Across the evidence base reviewed, higher intake of sugar-sweetened beverages repeatedly aligned with higher self-reported anxiety symptoms.

    Why drinks are under scrutiny

    Public health efforts have long focused on the physical harms of high-sugar diets, including obesity and type 2 diabetes. The authors argue that mental health outcomes linked to energy-dense, low-nutrient drinks have received comparatively less attention.

    The review covers a wide range of sweetened beverages commonly consumed by teens, including sodas, energy drinks, sweetened juices, and sweetened tea or coffee drinks. Many of these products can deliver large amounts of added sugar quickly, without offering lasting satiety.

    Correlation, not proven causation

    The researchers emphasize that the findings do not prove sugary drinks cause anxiety. Because the review synthesizes mainly observational, survey-based studies, it cannot determine whether sugary beverages lead to anxiety or whether anxious teens are more likely to consume them.

    They also note that shared factors could influence both outcomes, such as sleep problems, family stress, or broader lifestyle patterns. The authors say future research designed to test cause-and-effect is needed before drawing firm conclusions.

    What this could mean for families

    Even without proof of causality, the authors say the repeated link is concerning at a time when youth mental health problems are widely reported to be rising. They suggest sugary drink intake is a modifiable habit that could be considered alongside other daily factors like sleep, physical activity, and overall diet quality.

    The review’s lead author, Dr. Karim Khaled, previously completed doctoral work at Bournemouth University and now works at Lebanese American University in Beirut. Co-author Dr. Chloe Casey said mental health effects of diet deserve closer consideration in adolescent nutrition strategies.

  • Major Lancet review questions medicinal cannabis for anxiety and PTSD as trial evidence falls short

    Major Lancet review questions medicinal cannabis for anxiety and PTSD as trial evidence falls short

    A large review in The Lancet concludes there is no convincing evidence that medicinal cannabis improves symptoms of anxiety, depression or post-traumatic stress disorder. Researchers say the balance of data from randomized trials does not support routine prescribing for these mental health conditions.

    The analysis arrives as medical cannabis use has expanded rapidly in North America and elsewhere, including among people seeking relief from mood and trauma-related symptoms. The authors note that patient demand has often moved faster than the clinical evidence base.

    What the review examined

    The study pooled results from 54 randomized controlled trials conducted between 1980 and 2025, making it one of the broadest assessments of cannabinoids across mental health indications to date. It focused on both effectiveness and safety outcomes, comparing cannabis-based medicines with placebo or other controls.

    According to the authors, the evidence did not show meaningful improvements for anxiety, depression or PTSD when results were combined. They also cautioned that frequent use could be associated with harms, including psychotic symptoms and cannabis use disorder, and may delay more effective care.

    Potential benefits, but limited certainty

    The review found tentative signals that some cannabinoid preparations could help in a small number of other conditions, such as insomnia, tics or Tourette’s syndrome, autism-related symptoms, and cannabis use disorder. However, the authors stressed that the overall quality of evidence for these indications was low.

    They also pointed to areas where cannabis-based treatment is supported by stronger evidence, including specific epilepsy syndromes treated with cannabidiol, spasticity in multiple sclerosis, and certain types of pain. Even in these areas, they emphasized the need to match products and dosing to conditions studied in rigorous trials.

    Safety questions and regulation debate

    The authors said the findings should inform clinicians weighing prescriptions for mental health, particularly given varying product potency and formulations across markets. They argued that inconsistent regulation and marketing claims can leave patients with unclear expectations about benefits and risks.

    In substance use disorders, results differed by condition, with some evidence suggesting oral cannabinoid medicines may reduce cannabis smoking when combined with psychological therapy. But for cocaine-use disorder, the review reported increased cravings, indicating cannabis medicines should not be used for that purpose.

    Researchers called for clearer prescribing guidance and more high-quality trials that measure standardized mental health outcomes over longer follow-up periods. Until then, they said established, evidence-based treatments for anxiety, depression and PTSD should remain first-line care.

  • Ozempic and other GLP-1 drugs linked to lower depression and addiction risk in large Swedish study

    Ozempic and other GLP-1 drugs linked to lower depression and addiction risk in large Swedish study

    GLP-1 medications, such as semaglutide (Ozempic, Wegovy, and Rybelsus), commonly prescribed for diabetes and obesity may also be linked to better mental health outcomes, according to new research. The study found that people using these drugs had fewer psychiatric hospital visits and took less time off work due to mental health issues. The large-scale analysis was conducted by researchers from the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia.

    Obesity and diabetes are both tied to a higher risk of mental health problems. At the same time, people with psychiatric disorders are more likely to develop metabolic conditions such as obesity and diabetes. Scientists have long been exploring how these conditions overlap and whether treatments for physical health might also influence mental well-being.

    To investigate this connection, researchers analyzed data from nearly 100,000 individuals, including more than 20,000 who had used GLP-1 medications. Participants were tracked using Swedish national health registers from 2009 to 2022.

    Reduced Depression Anxiety and Psychiatric Care

    The findings showed that GLP-1 medications, especially semaglutide, were associated with fewer psychiatric-related hospital visits and reduced sickness absence. During periods when people were taking semaglutide, the need for such care dropped by 42% compared to periods without GLP-1 use. The risk of depression was 44% lower, while anxiety disorders were reduced by 38%.

    Lower Risk of Substance Use and Suicidal Behavior

    The study also found a notable decrease in substance use disorders among semaglutide users. Hospital care and time off work related to substance use were 47% lower during treatment periods. In addition, GLP-1 receptor agonists were linked to a reduced risk of suicidal behavior.

    One of the study’s authors, Professor Mark Taylor from Griffith University, said the findings were not entirely unexpected: “An earlier study examining Swedish registers found the use of GLP-1 medications to be associated with a reduced risk of alcohol use disorder. Alcohol-related problems often have downstream effects on mood and anxiety, so we expected the effect to be positive on these as well.”

    Why Might These Drugs Affect the Brain

    Even so, the strength of the associations surprised the research team. “Because this is a registry-based study, we cannot determine exactly why or how these medications affect mood symptoms, but the association was quite strong. It is possible that, in addition to factors such as reduced alcohol consumption, weight loss-related improvements in body image, or relief associated with better glycemic control in diabetes, there may also be direct neurobiological mechanisms involved — for example, through changes in the functioning of the brain’s reward system,” said Research Director, Docent Markku Lähteenvuo from the University of Eastern Finland.

    Strong Evidence but More Research Needed

    The results were published in The Lancet Psychiatry, a leading journal in the field. While earlier studies on GLP-1 medications and mental health have produced mixed findings, many of those studies were smaller. This large registry-based analysis adds stronger evidence, though further research is still needed to fully understand the link.

  • Ozempic and other GLP-1 drugs tied to lower depression and anxiety in large Swedish study, raising new questions about mental health benefits

    Ozempic and other GLP-1 drugs tied to lower depression and anxiety in large Swedish study, raising new questions about mental health benefits

    Popular GLP-1 medicines used for type 2 diabetes and weight loss, including Ozempic and Wegovy, may be linked to improved mental health outcomes, according to a large new analysis of Swedish health data. Researchers tracked changes in psychiatric care and work absence during periods when patients were using these drugs.

    The study, led by scientists from the University of Eastern Finland, Karolinska Institutet and Griffith University, examined national register data spanning 2009 to 2022. Nearly 100 000 people were included, with more than 20 000 having used a GLP-1 receptor agonist at some point during follow-up.

    What the study found

    Across the dataset, GLP-1 use was associated with fewer psychiatric hospital visits and fewer days of sickness absence related to mental health conditions. The strongest associations were reported for semaglutide, the active ingredient in Ozempic and Wegovy.

    During periods of semaglutide use, psychiatric hospital care and sickness absence were reported as 42% lower than during periods off treatment. The analysis also linked semaglutide exposure with a 44% lower risk of depression and a 38% lower risk of anxiety disorders.

    Signals beyond mood and anxiety

    The researchers also reported a lower rate of hospital care and work absence tied to substance use disorders during semaglutide treatment periods, with a reduction of 47%. They additionally found an association between GLP-1 receptor agonist use and reduced suicidal behavior, though the study design cannot determine causality.

    One author, Professor Mark Taylor of Griffith University, said the direction of the results aligned with earlier register-based research suggesting GLP-1 use may be associated with a reduced risk of alcohol use disorder. Because alcohol problems can worsen mood symptoms, the team said this could be one pathway behind the observed patterns.

    Why it may happen, and what it means

    Experts caution that registry studies can show links but cannot prove the drugs directly prevent depression or anxiety, since unmeasured factors could influence who starts or stays on treatment. Researchers said potential explanations range from improved blood sugar control and weight loss to reduced alcohol use and better quality of life.

    They also pointed to possible direct effects on the brain, including changes in reward-related pathways, as a hypothesis that needs targeted clinical research. The findings were published in The Lancet Psychiatry, adding weight to an ongoing debate as regulators and clinicians continue to watch for both potential benefits and risks affecting mental health.

  • Mokslininkai nustebino: viena psilocibino dozė gali keisti smegenis ir savijautą ištisą mėnesį

    Mokslininkai nustebino: viena psilocibino dozė gali keisti smegenis ir savijautą ištisą mėnesį

    Naujas tyrimas rodo, kad vienkartinė psilocibino dozė gali sukelti ne tik trumpalaikę psichodelinę patirtį, bet ir ilgiau išliekančius smegenų veiklos bei savijautos pokyčius. Mokslininkai teigia, kad daliai žmonių šie efektai gali būti juntami maždaug mėnesį.

    Psilocibinas yra psichoaktyvus junginys, natūraliai randamas kai kuriuose grybuose. Pastaraisiais metais jis vis dažniau tiriamas kaip potenciali priemonė gydant depresiją, nerimą ar priklausomybes, tačiau šįkart dėmesys sutelktas į sveikus, anksčiau jo nevartojusius dalyvius.

    Kaip vyko eksperimentas

    Tyrime dalyvavo 28 sveiki savanoriai, kurie psilocibino iki tol nebuvo bandę. Jie dalyvavo dviejose sesijose: pirmoje gavo 1 miligramą, kuris dažnai laikomas placebo doze, o po mėnesio antroje sesijoje gavo 25 miligramus, galinčius sukelti ryškią psichodelinę patirtį.

    Dalyviai pildė psichologinius testus, kuriais vertintas kognityvinis lankstumas, savijauta ir patirties metu gautos įžvalgos. Be to, buvo fiksuojami smegenų veiklos rodikliai, pasitelkiant EEG, funkcinį magnetinį rezonansą ir difuzijos tenzorinį vaizdinimą.

    EEG matavimai atlikti prieš sesiją ir praėjus 1, 2 bei 4,5 valandos po dozės, o magnetinio rezonanso tyrimai kartoti prieš psilocibino sesiją ir praėjus mėnesiui. Tyrėjai pažymi, kad dėl akivaizdaus patirties skirtumo daliai dalyvių buvo lengva atspėti, kurioje sesijoje gauta didesnė dozė.

    Ką parodė smegenų duomenys

    Analizuodami duomenis mokslininkai išskyrė ryšį tarp laikinai padidėjusios smegenų entropijos ir kitą dieną fiksuotų psichologinių įžvalgų. Entropija šiame kontekste apibūdina, kiek įvairiai ir plačiai svyruoja smegenų aktyvumo modeliai.

    Tyrėjų teigimu, didesnė entropija psilocibino poveikio metu ir stipresnės įžvalgos kitą dieną buvo susijusios su didesniu savijautos pagerėjimu po mėnesio. Kitaip tariant, ne vien pati medžiaga, bet ir patirties „turinys“ bei subjektyvus prasmingumas gali būti svarbi ilgalaikio efekto dalis.

    „Jau žinojome, kad psilocibinas gali būti naudingas gydant psichikos sutrikimus, tačiau dabar geriau suprantame, kaip tai gali veikti“, – sakė neurologas Robinas Carhartas-Harrisas.

    Kodėl tai svarbu ir kokie ribotumai

    Rezultatai papildo augantį mokslinių darbų lauką, kuriame psichodelikai vertinami ne kaip pramoginės medžiagos, o kaip galimos terapijos priemonės griežtai kontroliuojamoje klinikinėje aplinkoje. Praktikoje tai reiškia, kad ateityje daugiau dėmesio gali būti skiriama ne tik dozei, bet ir vadinamajam set ir setting, tai yra žmogaus psichologinei būsenai bei aplinkai.

    Vis dėlto mokslininkai pabrėžia, kad tai nedidelės apimties tyrimas, atliktas su sveikais dalyviais, todėl išvadų negalima tiesiogiai perkelti į klinikinį depresijos ar priklausomybių gydymą. Be to, entropijos idėja kaip universalaus psichodelinės būsenos žymens sulaukia kritikos, o patys autoriai pripažįsta, kad gali būti dar neatrasti pakankamai jautrūs būdai tiksliai fiksuoti ilgalaikius funkcinius smegenų pokyčius.

    Tyrimas publikuotas žurnale „Nature Communications“. Specialistai pabrėžia, kad psilocibino vartojimas be medicininės priežiūros gali kelti rizikų, ypač žmonėms, turintiems psichikos sutrikimų ar vartojantiems tam tikrus vaistus.